The store will not work correctly when cookies are disabled.
(R)-3-(4-Methoxy-benzenesulfonyl)-1-methyl-6-oxo-hexahydro-pyrimidine-4-carboxylic acid hydroxyamide
ID: ALA6973
Cas Number: 350697-43-7
PubChem CID: 44263877
Max Phase: Preclinical
Molecular Formula: C13H17N3O6S
Molecular Weight: 343.36
Molecule Type: Small molecule
Associated Items:
Names and Identifiers
Canonical SMILES: COc1ccc(S(=O)(=O)N2CN(C)C(=O)C[C@@H]2C(=O)NO)cc1
Standard InChI: InChI=1S/C13H17N3O6S/c1-15-8-16(11(7-12(15)17)13(18)14-19)23(20,21)10-5-3-9(22-2)4-6-10/h3-6,11,19H,7-8H2,1-2H3,(H,14,18)/t11-/m1/s1
Standard InChI Key: DRWHINQPSIPRHF-LLVKDONJSA-N
Molfile:
RDKit 2D
23 24 0 0 1 0 0 0 0 0999 V2000
2.9417 -2.2625 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
2.9417 -1.4375 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
2.2375 -2.6792 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.6542 -2.6792 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.6542 -3.5042 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
2.2375 -3.5042 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.9417 -3.9125 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.5167 -2.2667 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.7417 -1.2167 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.7292 -0.6375 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
2.1417 -1.6500 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
2.9417 -4.7375 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
1.5167 -1.4417 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
0.8042 -2.6792 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
3.9417 -0.4292 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.3167 -1.8000 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.3750 -3.9167 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.3167 -0.7875 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.7292 -0.2042 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.1125 -1.5792 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.0917 -2.2667 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
6.1167 -0.5667 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
6.7042 -1.1500 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2 1 1 0
3 1 1 0
4 1 1 0
5 4 1 0
6 3 1 0
7 5 1 0
3 8 1 6
9 2 1 0
10 2 2 0
11 2 2 0
12 7 2 0
13 8 2 0
14 8 1 0
15 9 1 0
16 9 2 0
17 5 1 0
18 20 2 0
19 15 2 0
20 16 1 0
21 14 1 0
22 18 1 0
23 22 1 0
6 7 1 0
18 19 1 0
M END
Associated Targets(Human)
Associated Targets(non-human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 343.36 | Molecular Weight (Monoisotopic): 343.0838 | AlogP: -0.62 | #Rotatable Bonds: 4 |
Polar Surface Area: 116.25 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 2 |
#RO5 Violations: ┄ | HBA (Lipinski): 9 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: 8.71 | CX Basic pKa: ┄ | CX LogP: -0.96 | CX LogD: -0.98 |
Aromatic Rings: 1 | Heavy Atoms: 23 | QED Weighted: 0.56 | Np Likeness Score: -1.02 |
References
1. Pikul S, Dunham KM, Almstead NG, De B, Natchus MG, Taiwo YO, Williams LE, Hynd BA, Hsieh LC, Janusz MJ, Gu F, Mieling GE.. (2001) Heterocycle-based MMP inhibitors with P2' substituents., 11 (8): [PMID:11327577] [10.1016/s0960-894x(01)00137-8] |
2. Verma RP, Hansch C.. (2007) Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs., 15 (6): [PMID:17275314] [10.1016/j.bmc.2007.01.011] |